Back to Search Start Over

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Source :
Business Wire. October 30, 2024
Publication Year :
2024

Abstract

* TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 expression without actionable genomic alterations * [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Business Wire
Publication Type :
News
Accession number :
edsgcl.814154597